Dare Bioscience (DARE) Other Non-Current Liabilities (2013 - 2026)
Dare Bioscience's (DARE) quarterly Other Non-Current Liabilities came in at $5.4 million in Q4 2025, up 13.51% YoY from $4.7 million in Q4 2024, and up 3.19% on a QoQ basis from $5.2 million in Q3 2025.
Dare Bioscience (DARE) Other Non-Current Liabilities (2013 - 2026) Analysis & Trends
Dare Bioscience (DARE) has 12 years of Other Non-Current Liabilities data on file, last reported at $5.4 million in Q4 2025.
- Quarterly Other Non-Current Liabilities rose 13.51% year-over-year to $5.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.4 million (up 13.51% YoY) and the FY2025 annual result came in at $5.4 million, up 13.51% from the prior year.
- Other Non-Current Liabilities rose to $5.4 million in Q4 2025, from $5.2 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $5.4 million in Q4 2025 to a low of $1.0 million in Q2 2021.
- A 4-year average of $4.3 million and a median of $4.6 million in 2024 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2021 — Other Non-Current Liabilities changed 0.0% — and 2024, when it rose 21.26%.
- Tracing DARE's Other Non-Current Liabilities over 4 years: stood at $1.0 million in 2021, then surged by 291.37% to $3.9 million in 2023, then climbed by 21.26% to $4.7 million in 2024, then climbed by 13.51% to $5.4 million in 2025.
- The last three Other Non-Current Liabilities figures came in at $5.4 million (Q4 2025), $5.2 million (Q3 2025), and $4.9 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Dare Bioscience | 12.36 Mn | -256,055.23 | -132,343.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.73 Mn |
| Dec 31, 2025 | 5.39 Mn |
| Sep 30, 2025 | 5.22 Mn |
| Jun 30, 2025 | 4.88 Mn |
| Mar 31, 2025 | 4.74 Mn |
| Dec 31, 2024 | 4.75 Mn |
| Sep 30, 2024 | 4.49 Mn |
| Jun 30, 2024 | 4.31 Mn |
| Mar 31, 2024 | 4.12 Mn |
| Dec 31, 2023 | 3.91 Mn |
| Jun 30, 2021 | 1.00 Mn |
| Dec 31, 2020 | 41,844.00 |
| Jun 30, 2020 | 1.00 Mn |
| Mar 31, 2020 | 284,200.00 |
| Dec 31, 2019 | 1.00 Mn |
| Sep 30, 2019 | 183,196.00 |
| Jun 30, 2019 | 203,948.00 |
| Mar 31, 2019 | 223,039.00 |
| Dec 31, 2018 | 9,711.00 |
| Mar 31, 2017 | 162,000.00 |